compounded semaglutide olympia pharmacy Liraglutide Olympia Pharmaceuticals

Alluvi Retatrutide vs Current GLP-1 Injections Feature Alluvi Retatrutide (Research) Wegovy Mounjaro Receptors targeted GLP-1 + GIP + Glucagon GLP-1 only GLP-1 + GIP Average Weight Loss ~24 % (48 weeks) ~15 % ~21 % Energy Expenditure Higher Moderate Moderate Regulatory Status UK Investigational Approved Approved (private) Safety Profile and Side Effects Observed Typical short-term effects reported in trials: Nausea, constipation or diarrhoea Mild fatigue Temporary appetite changes No long-term data exist yet for higher doses such as 40 mg

Pain is managed with paracetamol

Our retatrutide dosage guide explains the clinical benefits, provides clear dosage information and charts, and includes a practical calculator to help you and your doctor find the right approach for your health needs

Combining evening injection with a two-hour food buffer before injection and ginger tea before bed covers most cases